Is Amgen Stock a Buy Now?

This year hasn't been kind to biotech stocks, which as a group haven't kept pace with the broader market. The performance of the SPDR S&P Biotech ETF makes that clear. Leading drugmaker Amgen (NASDAQ: AMGN) has had a better showing, but it has still substantially trailed the S&P 500.

Still, long-term investors will want to know whether the drugmaker can deliver solid results over the long run -- and one year's worth of underperformance doesn't tell us much either way. For that, let's look into what's going on with Amgen and decide whether buying the biotech's shares today is worth it.

Source Fool.com

Amgen Inc. Aktie

Leicht aufwärts geht es heute für die Amgen Inc. Aktie. Seit gestern notiert das Papier um 0,17 % höher.
Mit 42 Buy-Einschätzungen und nur 4 Sell-Einschätzungen ist Amgen Inc. einer der Lieblinge unserere Community.
Ein unerwartetes Potenzial von -6.05% für Amgen Inc., obwohl das Kursziel von 340 € den aktuellen Kurs von 361.9 € unterschreitet.

Like: 0

AMGN

Teilen